Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Companies Collaborate to Develop Companion Diagnostic for Immunotherapy in HPV-Associated Cervical Dysplasia

March 18th 2021

QIAGEN and INOVIO Pharmaceuticals, Inc. are extending their collaborative efforts with a new agreement to develop liquid biopsy–based companion diagnostic assays for INOVIO agents, according to a news release from INOVIO.

Daratumumab Plus Rd Prolongs PFS in Frail, Newly Diagnosed, Transplant-Ineligible Myeloma

March 18th 2021

The addition of daratumumab to lenalidomide and dexamethasone resulted in improved progression-free survival vs Rd alone in patients with newly diagnosed multiple myeloma who were not eligible for transplant—even in frail patients.

Cilta-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma

March 17th 2021

Ciltacabtagene autoleucel has a manageable safety profile at its recommended phase 2 dose, and yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr. Kröger on Long-Term Results With Tandem Transplant in Multiple Myeloma

March 15th 2021

Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.

Dr. Martin on the Utility of Aggressive Frontline Treatment in Multiple Myeloma

March 15th 2021

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Dr. Kumar on the Challenges of Selecting Therapy in Heavily Pretreated Multiple Myeloma

March 12th 2021

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Dr. Richardson on the Toxicity Profile of Melphalan Flufenamide in Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.

ASH Takeaways and Future Directions for Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Sequencing BCMA-Targeted Agents in RRMM

March 11th 2021

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

Non-BCMA Specific Targets in RRMM

March 11th 2021

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

Dr. Schmidt on the Promise of Bispecific Antibodies in Myeloma

March 10th 2021

Timothy M. Schmidt, MD, discusses the promise of bispecific antibodies in patients with multiple myeloma.

Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple Myeloma

March 9th 2021

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Dr. Hari on Key Treatment Considerations for Relapsed/Refractory Myeloma

March 9th 2021

Parameswaran Hari, MD, MRCP, shares key considerations for the treatment of patients with relapsed/refractory multiple myeloma.

mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma

March 8th 2021

A phase 2 clinical trial has been initiated to evaluate Descartes-11, an mRNA CAR T-cell therapy, as a consolidative therapy in patients with newly diagnosed, high-risk multiple myeloma who have residual disease after induction therapy.

Teclistamab Shows Continued Promise in Relapsed/Refractory Multiple Myeloma

March 8th 2021

Teclistamab demonstrated encouraging clinical activity, along with a tolerable safety profile, in patients with relapsed/refractory multiple myeloma.

Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19

March 5th 2021

Maintenance treatment with lenalidomide was found to be a safe treatment for patients with multiple myeloma who are diagnosed with COVID-19, supporting use of the immunomodulatory drug in this patient population.

Melphalan Triplets Elicit Responses, Are Safe in Relapsed/Refractory Multiple Myeloma

March 5th 2021

The triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib demonstrated encouraging clinical activity and was well tolerated in patients with heavily pretreated relapsed/refractory multiple myeloma.

Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

March 4th 2021

Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.

Investigational BCMA Targets in RRMM

March 4th 2021

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

Targeting BCMA and CAR T Therapy in RRMM

March 4th 2021

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 